Literature DB >> 31641790

[Tuberculosis].

Christoph Lange1,2,3,4, Barbara Kalsdorf5,6, Florian P Maurer7, Jan Heyckendorf5,6.   

Abstract

Tuberculosis is a bacterial infectious disease that is usually transmitted by inhalation of droplets containing the bacteria. The World Health Organization (WHO) estimates that approximately 10 million patients were newly diagnosed with tuberculosis in 2017. Rapid diagnosis relies on a combination of imaging and microbiological, molecular, and, rarely, immunological tests. Genotypic methods enable early diagnosis and allow highly accurate prediction of drug resistance. Phenotypic (culture-based) methods are the diagnostic gold standard. Standard management of patients with pan drug-susceptible pulmonary tuberculosis includes a combination of rifampicin, isoniazid, ethambutol and pyrazinamide for 2 months followed by rifampicin and isoniazid for additional 4 months, which leads to cure rates of >80%. With individualized treatment schemes, similar cure rates can be achieved for patients with multidrug-resistant tuberculosis.

Entities:  

Keywords:  Interferon-γ release tests; Mycobacterium tuberculosis; Tuberculosis therapy; Tuberculosis, multidrug-resistant; Tuberculosis, pulmonary

Mesh:

Substances:

Year:  2019        PMID: 31641790     DOI: 10.1007/s00108-019-00685-z

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  26 in total

Review 1.  Interferon-γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis.

Authors:  M Sester; G Sotgiu; C Lange; C Giehl; E Girardi; G B Migliori; A Bossink; K Dheda; R Diel; J Dominguez; M Lipman; J Nemeth; P Ravn; S Winkler; E Huitric; A Sandgren; D Manissero
Journal:  Eur Respir J       Date:  2010-09-16       Impact factor: 16.671

Review 2.  Treatment of Tuberculosis.

Authors:  C Robert Horsburgh; Clifton E Barry; Christoph Lange
Journal:  N Engl J Med       Date:  2015-11-26       Impact factor: 91.245

3.  Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin.

Authors:  C Magis-Escurra; H M J Later-Nijland; J W C Alffenaar; J Broeders; D M Burger; R van Crevel; M J Boeree; A R T Donders; R van Altena; T S van der Werf; R E Aarnoutse
Journal:  Int J Antimicrob Agents       Date:  2014-06-09       Impact factor: 5.283

4.  The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study.

Authors:  Nikos P Spyridis; Panayotis G Spyridis; Anna Gelesme; Vana Sypsa; Mina Valianatou; Flora Metsou; Dimitris Gourgiotis; Maria N Tsolia
Journal:  Clin Infect Dis       Date:  2007-08-06       Impact factor: 9.079

5.  Evaluation of PCR in detection of Mycobacterium tuberculosis from formalin-fixed, paraffin-embedded tissues: comparison of four amplification assays.

Authors:  G Marchetti; A Gori; L Catozzi; L Vago; M Nebuloni; M C Rossi; A D Esposti; A Bandera; F Franzetti
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

6.  Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis.

Authors:  Bongani M Mayosi; Mpiko Ntsekhe; Jackie Bosch; Shaheen Pandie; Hyejung Jung; Freedom Gumedze; Janice Pogue; Lehana Thabane; Marek Smieja; Veronica Francis; Laura Joldersma; Kandithalal M Thomas; Baby Thomas; Abolade A Awotedu; Nombulelo P Magula; Datshana P Naidoo; Albertino Damasceno; Alfred Chitsa Banda; Basil Brown; Pravin Manga; Bruce Kirenga; Charles Mondo; Phindile Mntla; Jacob M Tsitsi; Ferande Peters; Mohammed R Essop; James B W Russell; James Hakim; Jonathan Matenga; Ayub F Barasa; Mahmoud U Sani; Taiwo Olunuga; Okechukwu Ogah; Victor Ansa; Akinyemi Aje; Solomon Danbauchi; Dike Ojji; Salim Yusuf
Journal:  N Engl J Med       Date:  2014-09-01       Impact factor: 91.245

7.  High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.

Authors:  Martin J Boeree; Norbert Heinrich; Rob Aarnoutse; Andreas H Diacon; Rodney Dawson; Sunita Rehal; Gibson S Kibiki; Gavin Churchyard; Ian Sanne; Nyanda E Ntinginya; Lilian T Minja; Robert D Hunt; Salome Charalambous; Madeleine Hanekom; Hadija H Semvua; Stellah G Mpagama; Christina Manyama; Bariki Mtafya; Klaus Reither; Robert S Wallis; Amour Venter; Kim Narunsky; Anka Mekota; Sonja Henne; Angela Colbers; Georgette Plemper van Balen; Stephen H Gillespie; Patrick P J Phillips; Michael Hoelscher
Journal:  Lancet Infect Dis       Date:  2016-10-26       Impact factor: 25.071

8.  A comprehensive characterization of PncA polymorphisms that confer resistance to pyrazinamide.

Authors:  Adam N Yadon; Kashmeel Maharaj; John H Adamson; Yi-Pin Lai; James C Sacchettini; Thomas R Ioerger; Eric J Rubin; Alexander S Pym
Journal:  Nat Commun       Date:  2017-09-19       Impact factor: 14.919

9.  Clinical Application of Interferon-γ Release Assays for the Prevention of Tuberculosis in Countries with Low Incidence.

Authors:  Christoph Lange; Anna M Mandalakas; Barbara Kalsdorf; Claudia M Denkinger; Martina Sester
Journal:  Pathog Immun       Date:  2016-01-04

10.  Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa.

Authors:  Karen Shean; Elizabeth Streicher; Elize Pieterson; Greg Symons; Richard van Zyl Smit; Grant Theron; Rannakoe Lehloenya; Xavier Padanilam; Paul Wilcox; Tommie C Victor; Paul van Helden; Martin P Grobusch; Martin Groubusch; Robin Warren; Motasim Badri; Keertan Dheda
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

View more
  1 in total

1.  Screening of Biomarkers and Toxicity Mechanisms of Rifampicin-Induced Liver Injury Based on Targeted Bile Acid Metabolomics.

Authors:  Yang Deng; Xilin Luo; Xin Li; Yisha Xiao; Bing Xu; Huan Tong
Journal:  Front Pharmacol       Date:  2022-06-10       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.